Download available for users with full-size access enabled
Onyx
In relapsed multiple myeloma,
TO DISRUPT THE CYCLE OF DIMINISHING RESPONSES,
Is depth the answer?
Relapsed multiple myeloma:
A COMPLEX AND CHALLENGING DISEASE
Today, there is no established cure for multiple myeloma (MM). It is characterized by a recurring pattern of relapse. The majority of patients with relapsed MM do not achieve optimal responses regardless of treatment regimen, and clinical benefit decreases with each subsequent line of therapy.
I Improving long-term outcomes is a primary goal of relapsed MM treatment.
Relapsed multiple myeloma:
AIMING FOR LONG-TERM SUCCESS
Deep responses have been found to statistically correlate to progression-free survival across patient type and treatment setting. In an analysis of 1175 elderly patients with MM, the impact of complete response on long-term outcome was confirmed regardless of baseline patient characteristics, including age.1 Elderly patients and other high-risk patients with relapsed MM may achieve similar response rates to the rest of the population; therefore, aiming for deep responses (complete response) for all patients should be the goal.
Achieving and sustaining responses should be a priority in the treatment of relapsed MM. A prolonged or durable complete response is an independent posttreatment variable associated with improved survival. Continuous treatment, even after an initial response has been achieved, may further deepen the response.
I As the treatment landscape evolves, both deep and durable responses should be the expectation for relapsed multiple myeloma.
Brand: Onyx Country/Market: USA, North America Target: Healthcare Professional (HCP) Size/duration: Single-page Publication/Aired:
Blood - May 28, 2014 Brand files
Onyx